(S)-N-cyclohexyl-2-methyl-5-(6-oxo-2-(4-(4,4,4-trifluorobutoxy)phenyl)-2-(trifluoromethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzamide

ID: ALA4864768

Chembl Id: CHEMBL4864768

PubChem CID: 164623715

Max Phase: Preclinical

Molecular Formula: C30H32F6N2O3

Molecular Weight: 582.58

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccc(C2=C(C(=O)NC3CCCCC3)C(=O)N[C@@](c3ccc(OCCCC(F)(F)F)cc3)(C(F)(F)F)C2)cc1

Standard InChI:  InChI=1S/C30H32F6N2O3/c1-19-8-10-20(11-9-19)24-18-28(30(34,35)36,21-12-14-23(15-13-21)41-17-5-16-29(31,32)33)38-27(40)25(24)26(39)37-22-6-3-2-4-7-22/h8-15,22H,2-7,16-18H2,1H3,(H,37,39)(H,38,40)/t28-/m0/s1

Standard InChI Key:  PKWVFKGYTPVIRB-NDEPHWFRSA-N

Alternative Forms

  1. Parent:

    ALA4864768

    ---

Associated Targets(Human)

MGAT2 Tchem Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (703 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mgat2 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (71 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 582.58Molecular Weight (Monoisotopic): 582.2317AlogP: 6.90#Rotatable Bonds: 8
Polar Surface Area: 67.43Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 10.26CX Basic pKa: CX LogP: 6.71CX LogD: 6.71
Aromatic Rings: 2Heavy Atoms: 41QED Weighted: 0.20Np Likeness Score: -0.49

References

1. Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P..  (2021)  Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.,  64  (19.0): [PMID:34613725] [10.1021/acs.jmedchem.1c01356]

Source